Bipolar Depression Pipeline Market 2020 Insight, Key Players are Sunovion, Sumitomo Pharmaceutical, H. Lundbeck A/S, NeuroRx, Inc., Korea Otsuka Pharmaceutical Co., Ltd., Intra-Cellular Therapies, Inc., Janssen Research & Development, Forest Laboratories,

Bipolar Depression Pipeline Market Insight, 2020, report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Bipolar Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
- Global coverage
Key Players
- Sunovion
- Sumitomo Pharmaceutical
- H. Lundbeck A/S
- NeuroRx, Inc.
- Korea Otsuka Pharmaceutical Co., Ltd.
- Intra-Cellular Therapies, Inc.
- Janssen Research & Development
- Forest Laboratories
- Celon Pharma
- Astellas Pharma Inc
- Iltoo Pharma

Key Products
- Lurasidone
- Vortioxetine
- Lumateperone
- JNJ-18038683
- Cariprazine
- Esketamine
- FK949E
- ILT101

Get Free Sample Copy of this Research Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=3729261

Bipolar Depression Understanding

Bipolar Depression: Overview
Bipolar disorder, formerly called manic depression, is a mental health condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression).

Symptoms

During the manic phase, symptoms can include:
- High level of energy and activity
- Irritable mood
- Decreased need for sleep
- Exaggerated, puffed-up self-esteem ("grandiosity")
- Rapid or "pressured" speech
- Rapid thoughts
- Tendency to be easily distracted
- Increased recklessness
- False beliefs (delusions) or false perceptions (hallucinations)

Diagnosis

Since there are no medical tests to establish this diagnosis, a mental health professional diagnoses bipolar disorder based on a person's history and symptoms. The diagnosis is based not just on the current symptoms, but also take into account the problems and symptoms that have occurred through a person's life.

Treatment

A combination of medication and talk therapy is most helpful. Often more than one medication is needed to keep the symptoms in check.

Mood Stabilizers: The best-known and oldest mood stabilizer is lithium carbonate, which can reduce the symptoms of mania and prevent them from returning.

Antipsychotic Medications: In recent years, studies have shown that some of the newer antipsychotic medications can be effective for controlling bipolar disorder symptoms. Side effects often have to be balanced against the helpful effects of these drugs:
- Olanzapine: sleepiness, dry mouth, dizziness and weight gain.
- Risperidone: sleepiness, restlessness and nausea.
- Quetiapine: dry mouth, sleepiness, weight gain and dizziness.
- Ziprasidone: sleepiness, dizziness, restlessness, nausea and tremor.
- Aripiprazole: nausea, stomach upset, sleepiness (or sleeplessness) or restlessness.
- Asenapine: sleepiness, restlessness, tremor, stiffness, dizziness, mouth or tongue numbness.
Get 20% Discount on this Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=3729261

Bipolar Depression Emerging Drugs Chapters

This segment of the Bipolar Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bipolar Depression Emerging Drugs
- Lumateperone: Intra-Cellular Therapies

Lumateperone is a butyrophenone atypical antipsychotic developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the treatment of schizophrenia, and currently in development for bipolar depression and other neurological indications. The most common side effects include sleepiness and dry mouth.
- Zuranolone: SAGE Therapeutics

Zuranolone is an investigational medication which is under development by SAGE Therapeutics for the treatment of depressive disorders and a variety of other indications. It is a synthetic, orally active, inhibitory pregnane neurosteroid, and acts as a positive allosteric modulator of the GABAA receptor.

Further product details are provided in the report……..

Bipolar Depression: Therapeutic Assessment

This segment of the report provides insights about the different Bipolar Depression drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Bipolar Depression

There are approx. 20+ key companies which are developing the therapies for Bipolar Depression. The companies which have their Bipolar Depression drug candidates in the most advanced stage, i.e. phase III include, SAGE Therapeutics.
- Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

- Route of Administration

Bipolar Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=3729261

Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bipolar Depression: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bipolar Depression therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bipolar Depression drugs.

Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Bipolar Depression R&D. The therapies under development are focused on novel approaches to treat/improve Bipolar Depression.
- In July 2019, Intra-Cellular Therapies announced top-line results from two Phase 3 clinical trials (Study 401 and Study 404) evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. In Study 404, lumateperone 42 mg met the primary endpoint for improvement in depression as measured by change from baseline versus placebo on the MADRS total score (p

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

+ 1 888 391 5441
sales@reportsandreports.com

This release was published on openPR.